Drug Profile
Satigrel
Alternative Names: E 5510Latest Information Update: 29 Dec 1999
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Nonindustrial source
- Class Antiplatelets
- Mechanism of Action Cyclooxygenase inhibitors; Phospholipase inhibitors; Phosphoric diester hydrolase inhibitors; Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Renal transplant rejection; Stroke; Thrombosis
Most Recent Events
- 29 Dec 1999 Discontinued-Clinical for Renal transplant rejection in Japan (Unknown route)
- 29 Dec 1999 Discontinued-Clinical for Thrombosis in Ireland (PO)
- 29 Dec 1999 Discontinued-Clinical for Thrombosis in USA (PO)